Genetic heterogeneity of hereditary diseases of nervous system: problems and solutions
https://doi.org/10.17650/2222-8721-2012-0-1-11-18
Abstract
A hereditary disorders of the nervous system is one of the largest group of human monogenic disorders with high-grade genetic heterogeneity and clinical polymorphism. The main types of genetic heterogeneity and their possible causes are explained by giving typical examples of different nosological forms. The basic problems and feasible solution of medico-genetic counseling and education of high-risk families in case of genetic heterogeneity are discussed.
About the Authors
E. L. Dadali
Research Centre for Medical Genetic of Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
E. K. Ginter
Research Centre for Medical Genetic of Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. B. Polyakov
Research Centre for Medical Genetic of Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Горбунова В.Н., Савельева-Васильева Е.А., Красильников В.В. Молекулярная неврология. Часть 1. СПб.: Интермедика, 2000.
2. Иллариошкин С.Н., Иванова-Смоленская И.А., Маркова Е.Д. ДНК-диагностика и медико-генетическое консультирование в неврологии. М.: МИА, 2002.
3. Иллариошкин С.Н., Руденская Г.Е., Иванова-Смоленская И.А. и др. Наследственные атаксии и параплегии. М.: МИА, 2006.
4. Тверская С.М., Чухрова А.Л., Дадали Е.Л. и др. Разнообразие клинических проявлений моногенных наследственных заболеваний, обусловленных мутациями в одном гене. Мед генетика 2007;6:3−11.
5. Aebi U., Cohn J., Buchle L. et al. The nuclear lamina is a meshwork of intermediate filament type filaments. Nature 1986;323:560−4.
6. Angelini C. Limb-girdle muscular dystrophies heterogeneity of clinical phenotypes and pathogenetic mechanisms. Acta Myol 2004;23:130−13.
7. Campbell L., Potter A., Ignatius J. et al. Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype. Am J Hum Genet 1997;61:40−50.
8. Hentati A., Lamy C.,Melki J. et al. Clinical and genetic heterogeneity of Charcot-Marie-Tooth disease. Genomiсs 1992;126:155−7.
9. Давиденков С.Н. Проблема полиморфизма наследственных болезней нервной системы. Л.: Изд-во ВИЭМ, 1934. 139 с.
10. Дадали Е.Л., Щагина О.А, Рыжкова О.П. и др. Особенности клинических проявлений поясно-конечностной прогрессирующей мышечной дистрофии типа 2А у российских больных. Журн неврол и психиатр 2010;4:79−83.
11. Щагина О.А., Дадали Е.Л., Поляков А.В. Нарушение структуры и функции хондриома как причина возникновения наследственной моторносенсорной нефропатии 2А типа. Мед генетика 2006;5(3):13−7.
12. Berger P.,Young P., Suter U. Molecular cell biology of Charcot−Marie−Tooth disease. Neurogenetics 2002;4:1−15.
13. Boerkoel C.F., Takashima H., Garcia C.A. et al. Charcot−Marie−Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol 2002;51:190−201.
14. Houlden H., Reilly M.M. Molecular genetics of autosomal-dominant demyelinating Charcot−Marie−Tooth disease. Neuromolecular Med 2006; 8(1−2):43−62.
15. Keller M.P., Chance P.E. Inherited neuropathies: from gene to disease. Brain Pathol 1999;9:327−41.
16. Lewis R.A. Clinical electrophysiology and pathophysiology: lessons from studies in demyelinating neuropathies. J Neurol Sci 2004;220(1−2):125−6.
17. Руденская Г.Е., Тверская С.М., Чухрова А.Л. и др. Разнообразие болезней, обусловленных мутациями гена LMNA. Мед генетика 2004; 3:569−76.
18. Young S.G., Meta M., Yang S.H., Fong L.G. Prelamin А farnesylation and progeroid syndromes. J Biol Chem 2006;281(52):39741−5.
19. Stephen L. Maidment, Juliet A. Ellis Muscular dystrophies, dilated cardiomyopathy, lipodystrophy and
20. neuropathy: the nuclear connection. Expert Reviews in Molecular Medicine: http://www.expertreviews.org/02004842h. htm. — 2002
21. Cobben J.M., van der Steege G., Grootscholten P. et al. Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy. Am J Hum Genet 1995;57:805−8.
22. Samilchuk E., D’Souza B., Bastaki L. Deletion analysis of the SMN and NAIP genes in Kuwaiti patients with spinal muscular atrophy. Hum Genet 1996; 98:524−7.
23. Jedrzejowska M., Borkowska J., Zimowski J. et al. Unaffected patients with a homozygous absence of the SMN1 gene. Europ J Hum Genet 2008;16:930−4.
24. Oprea G.E., Kroeber S., McWhorter M.L. et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 2008;320: 524−7.
25. Угаров И.В., Дадали Е.Л., Евдокименков В.А. Информационно-поисковая диагностическая система для наследственных нервно-мышечных за- болеваний. Мед генетика 2004;9:428−32.
Review
For citations:
Dadali E.L., Ginter E.K., Polyakov A.B. Genetic heterogeneity of hereditary diseases of nervous system: problems and solutions. Neuromuscular Diseases. 2012;(1):11-18. (In Russ.) https://doi.org/10.17650/2222-8721-2012-0-1-11-18
Views:
1624
Email this article 